Metraipolis › archive › dc_f8b22c4bc875

15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study — Europe PMC PMID:41514667

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41514667
DOI
10.3390/cancers18010159
License (as archived)
solo-consultazione
Archived
2026-11-07T03:14:37.534Z
SHA-256 of the archived text
8cfe64d9c30c5aed080214f632c1bd1605d886de0e0988304480e9cdcafe7445
Stable URL of this page
https://metraipolis.com/documento/dc_f8b22c4bc875

How to cite

15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study — Europe PMC PMID:41514667 — Europe PMC (en), https://europepmc.org/article/MED/41514667 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f8b22c4bc875 (Metraipolis archive dc_f8b22c4bc875, sha256 8cfe64d9c30c5aed080214f632c1bd1605d886de0e0988304480e9cdcafe7445)
BibTeX
@misc{dcf8b22c4bc875,
  title = {15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study — Europe PMC PMID:41514667},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41514667},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f8b22c4bc875; sha256 8cfe64d9c30c5aed080214f632c1bd1605d886de0e0988304480e9cdcafe7445},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41514667. Agents can read the archived copy with the MCP tool read_document.